Literature DB >> 12559272

Retroperitoneal laparoscopic cryoablation of small renal tumors: intermediate results.

David I Lee1, David E McGinnis, Rick Feld, Stephen E Strup.   

Abstract

OBJECTIVES: To present our experience with laparoscopic renal cryoablation with up to 3 years of follow-up. Laparoscopic renal cryoablation remains a viable option for the treatment of small peripheral renal masses in patients with significant comorbidities. Although partial nephrectomy has been shown to be a safe and reliable method of renal parenchymal preservation, laparoscopic cryoablation still requires longer term data to prove its efficacy.
METHODS: Twenty patients with small renal masses (1.4 to 4.5 cm) underwent laparoscopic renal cryosurgery at our institution. A retroperitoneal laparoscopic approach was used to expose the kidney. Intraoperative ultrasound guidance was used to localize the lesions and monitor iceball formation. A double-freeze technique was used. Needle biopsies of solid masses were performed intraoperatively.
RESULTS: Renal biopsies revealed renal cell carcinoma in 11 of the 20 patients. Of these 11 patients, none had evidence of recurrent disease at last follow-up, and follow-up scans showed no enhancement of any lesions. Of the 8 patients with follow-up of 2 years or greater, 4 had complete resolution of the renal lesions. The remainder had lesions that were reduced and stable in size. Complications included surgical re-exploration to evaluate pancreatic injury in 1 patient and failure to ablate a lesion in another.
CONCLUSIONS: Laparoscopic renal cryoablation appears to be an effective tool for ablation of small renal lesions. A moderate length of follow-up continues to demonstrate efficacy because no patients had growth of treated pathologic lesions or developed metastasis to date. Continued maturation of data is necessary to determine the long-term efficacy.

Entities:  

Mesh:

Year:  2003        PMID: 12559272     DOI: 10.1016/s0090-4295(02)02004-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

1.  Thermal protection during percutaneous thermal ablation of renal cell carcinoma.

Authors:  Anthony W Kam; Peter J Littrup; McClellan M Walther; Julia Hvizda; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2004-07       Impact factor: 3.464

2.  Robot-assisted retroperitoneal renal cryoablation.

Authors:  Manish N Patel; Mani Menon; Craig G Rogers
Journal:  J Robot Surg       Date:  2008-11-11

3.  Ablative therapies for renal tumors.

Authors:  Rajan Ramanathan; Raymond J Leveillee
Journal:  Ther Adv Urol       Date:  2010-04

Review 4.  Oncologic outcomes for ablative therapy of kidney cancer.

Authors:  Sangtae Park; Jeffrey A Cadeddu; W Bruce Shingleton
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

Review 5.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

6.  Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis.

Authors:  David A Kunkle; Robert G Uzzo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

Review 7.  Computed tomography and magnetic resonance imaging appearance of renal neoplasms after radiofrequency ablation and cryoablation.

Authors:  Satomi Kawamoto; Stephen B Solomon; David A Bluemke; Elliot K Fishman
Journal:  Semin Ultrasound CT MR       Date:  2009-04       Impact factor: 1.875

Review 8.  [Energy ablative therapy of renal tumours].

Authors:  H C Klingler
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

Review 9.  Kidney cancer ablative therapy: indications and patient selection.

Authors:  Daniel S Lehman; Jaime Landman
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

Review 10.  Radiofrequency ablation of renal tumors.

Authors:  Andreas H Mahnken; Rolf W Günther; Josef Tacke
Journal:  Eur Radiol       Date:  2004-05-19       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.